Display options
Cite
Wu H, Li P, Shao N, et al. Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-β in acute myeloid leukemia. Oncol Lett. 2012;3(5):1119-1123doi: 10.3892/ol.2012.614.
Wu, H., Li, P., Shao, N., Ma, J., Ji, M., Sun, X., Ma, D., & Ji, C. (2012). Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-β in acute myeloid leukemia. Oncology letters, 3(5), 1119-1123. https://doi.org/10.3892/ol.2012.614
Wu, Hao, et al. "Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-β in acute myeloid leukemia." Oncology letters vol. 3,5 (2012): 1119-1123. doi: https://doi.org/10.3892/ol.2012.614
Wu H, Li P, Shao N, Ma J, Ji M, Sun X, Ma D, Ji C. Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-β in acute myeloid leukemia. Oncol Lett. 2012 May;3(5):1119-1123. doi: 10.3892/ol.2012.614. Epub 2012 Feb 20. PMID: 22783403; PMCID: PMC3389635.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2012 May;3(5):1119-1123. doi: 10.3892/ol.2012.614. Epub 2012 Feb 20.

Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-β in acute myeloid leukemia.

Oncology letters

Hao Wu, Peng Li, Na Shao, Jingjing Ma, Min Ji, Xiulian Sun, Daoxin Ma, Chunyan Ji

Affiliations

  1. Department of Hematology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.

PMID: 22783403 PMCID: PMC3389635 DOI: 10.3892/ol.2012.614

Abstract

Acute myeloid leukemia (AML) is the most common hematological malignancy in adults, characterized by distorted proliferation and the development of myeloid cells and their precursors in the blood and bone marrow. Interleukin 35 (IL-35), a novel inhibitory cytokine secreted by regulatory T (Treg) cells is a novel potential target used for the therapeutic manipulation of Treg activity in order to treat cancer and autoimmune diseases. To investigate the role and imbalance of Treg-related cytokines in the pathogenesis of AML, we measured the plasma concentration of three Treg-associated cytokines [IL-35, IL-10 and transforming growth factor-β (TGF-β)] and evaluated their clinical relevance. The concentration of IL-35, IL-10 and TGF-β in plasma specimens from 55 patients with AML [27 newly diagnosed (ND) patients and 28 in complete remission (CR)] and 24 controls was analyzed using the enzyme-linked immunosorbent assay method. Significantly higher levels of plasma IL-35 and IL-10 were observed in AML ND patients compared with healthy controls or AML CR patients. IL-10 concentrations were positively correlated with TGF-β, whereas no correlations were found between the other cytokines. IL-10 levels were positively correlated with white blood cell (WBC) and neutrophil (NEU) count but there were no correlations between IL-35 and TGF-β with WBC and NEU count. In conclusion, we demonstrated for the first time that AML ND patients have increased plasma concentrations of IL-35, suggesting that this cytokine is involved in the pathophysiological process of the disease, and that further research is required to address this issue.

References

  1. Clin Exp Immunol. 2010 Aug;161(2):223-32 - PubMed
  2. Ann Intern Med. 1985 Oct;103(4):620-5 - PubMed
  3. Nat Immunol. 2010 Dec;11(12):1093-101 - PubMed
  4. Leuk Lymphoma. 2001 Mar;41(1-2):161-8 - PubMed
  5. BMC Immunol. 2010 Jul 09;11:38 - PubMed
  6. J Biol Chem. 2000 Dec 22;275(51):40282-7 - PubMed
  7. Mol Oncol. 2010 Aug;4(4):335-46 - PubMed
  8. Methods Mol Biol. 2011;707:3-17 - PubMed
  9. Nature. 2007 Nov 22;450(7169):566-9 - PubMed
  10. Immunology. 2011 Jul;133(3):296-306 - PubMed
  11. N Engl J Med. 1999 Sep 30;341(14):1051-62 - PubMed
  12. Br J Haematol. 1976 Aug;33(4):451-8 - PubMed
  13. Blood. 2006 May 1;107(9):3639-46 - PubMed
  14. Cancer Res. 1997 Feb 1;57(3):476-80 - PubMed
  15. Int J Hematol. 1997 Dec;66(4):445-50 - PubMed
  16. Blood. 1990 Apr 1;75(7):1540-8 - PubMed
  17. Leukemia. 1995 Nov;9(11):1910-20 - PubMed
  18. Int J Cancer. 2011 Sep 15;129(6):1373-81 - PubMed
  19. Clin Cancer Res. 2009 May 15;15(10):3325-32 - PubMed
  20. Eur J Haematol. 2005 Dec;75(6):468-76 - PubMed
  21. Cancer Surv. 1992;12:81-103 - PubMed
  22. Lancet. 2006 Nov 25;368(9550):1894-907 - PubMed
  23. Eur J Immunol. 2007 Nov;37(11):3021-9 - PubMed
  24. Oncogene. 2001 Jan 4;20(1):88-96 - PubMed
  25. Clin Exp Immunol. 2009 Nov;158(2):199-204 - PubMed
  26. Blood. 1996 Aug 1;88(3):1035-45 - PubMed
  27. Leuk Res. 2011 Mar;35(3):363-8 - PubMed
  28. Oncol Rep. 2008 Sep;20(3):677-82 - PubMed
  29. J Immunother (1991). 2001 Sep-Oct;24(5):392-407 - PubMed
  30. Blood. 2000 Jun 15;95(12):3945-50 - PubMed
  31. Blood. 2006 May 15;107(10):3940-9 - PubMed
  32. Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12041-6 - PubMed
  33. J Clin Oncol. 1990 May;8(5):813-9 - PubMed
  34. J Immunol. 2010 Jun 15;184(12):7144-53 - PubMed
  35. Curr Opin Immunol. 2007 Apr;19(2):217-23 - PubMed
  36. J Biol Regul Homeost Agents. 2010 Apr-Jun;24(2):131-5 - PubMed
  37. Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1104-9 - PubMed
  38. J Immunol. 1993 Mar 15;150(6):2418-30 - PubMed
  39. Immunol Res. 2005;32(1-3):155-68 - PubMed
  40. Blood. 2004 Mar 1;103(5):1755-62 - PubMed

Publication Types